Structure Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Structure Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($65.71M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($61.66M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($61.66M) | Aug 6, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($46.83M) | Nov 6, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($46.83M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($46.83M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($33.98M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($26.03M) | Aug 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($26.03M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($26.04M) | May 8, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($26.04M) | Aug 6, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($26.04M) | Nov 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($23.86M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($23.28M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($23.28M) | Nov 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($17.98M) | Aug 8, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($17.98M) | Nov 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($17.98M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($12.42M) | Nov 17, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($13.95M) | Nov 17, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($73.79M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($70.45M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($56.31M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($45.84M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($33.32M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($32.02M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($26.15M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($25.99M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($19.65M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($12.69M) | Nov 17, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($13.96M) | Nov 17, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($12.95M) | May 11, 2023 |